Sigilon Therapeutics, Inc. (SGTX) Financial Statements (2025 and earlier)

Company Profile

Business Address 100 BINNEY STREET
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2023
MRQ
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:69,600123,400
Cash and cash equivalents42,066107,143
Short-term investments27,56016,213
Other undisclosed cash, cash equivalents, and short-term investments (26)44
Restricted cash and investments250250
Receivables2,17159
Other undisclosed current assets2,3902,685
Total current assets:74,411126,394
Noncurrent Assets
Operating lease, right-of-use asset8,97912,863
Property, plant and equipment2,8543,994
Restricted cash and investments1,0341,118
Total noncurrent assets:12,86717,975
TOTAL ASSETS:87,278144,369
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6,1406,286
Employee-related liabilities3,071
Accounts payable9362,344
Accrued liabilities5,204871
Debt 13,3343,334
Other undisclosed current liabilities11,52025,268
Total current liabilities:30,99434,888
Noncurrent Liabilities
Long-term debt and lease obligation 12,02126,988
Long-term debt, excluding current maturities 12,02118,411
Liabilities, other than long-term debt5,121 
Other liabilities 233 
Operating lease, liability4,8888,577
Other undisclosed noncurrent liabilities  (3,244)
Total noncurrent liabilities:17,14232,321
Total liabilities:48,13667,209
Equity
Equity, attributable to parent39,14277,160
Common stock3232
Additional paid in capital296,339290,377
Accumulated other comprehensive loss(429)(10)
Accumulated deficit(256,800)(213,239)
Total equity:39,14277,160
TOTAL LIABILITIES AND EQUITY:87,278144,369

Income Statement (P&L) ($ in thousands)

6/30/2023
TTM
12/31/2022
12/31/2021
Revenues12,9449,599
Revenue from related parties  9,504
Gross profit:12,9449,599
Operating expenses(56,610)(85,235)
Operating loss:(43,666)(75,636)
Nonoperating income (expense)105(1,675)
Other nonoperating income1,44955
Interest and debt expense(2,290)(1,988)
Loss from continuing operations:(45,851)(79,299)
Loss before gain (loss) on sale of properties:(79,299)
Other undisclosed net income2,2901,988
Net loss:(43,561)(77,311)
Other undisclosed net income attributable to parent  
Net loss available to common stockholders, diluted:(43,561)(77,311)

Comprehensive Income ($ in thousands)

6/30/2023
TTM
12/31/2022
12/31/2021
Net loss:(43,561)(77,311)
Other comprehensive income (loss)(419)(10)
Comprehensive loss:(43,980)(77,321)
Other undisclosed comprehensive income, net of tax, attributable to parent  
Comprehensive loss, net of tax, attributable to parent:(43,980)(77,321)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: